Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Effectiveness and selectivity of a heroin conjugate vaccine to attenuate heroin, 6-acetylmorphine, and morphine antinociception in rats: Comparison with naltrexone.

Schwienteck KL, Blake S, Bremer PT, Poklis JL, Townsend EA, Negus SS, Banks ML.

Drug Alcohol Depend. 2019 Aug 24;204:107501. doi: 10.1016/j.drugalcdep.2019.06.006. [Epub ahead of print]

PMID:
31479865
2.

The Rise and Fall of Kappa-Opioid Receptors in Drug Abuse Research.

Banks ML.

Handb Exp Pharmacol. 2019 Aug 29. doi: 10.1007/164_2019_268. [Epub ahead of print]

PMID:
31463605
3.

Vaccine blunts fentanyl potency in male rhesus monkeys.

Tenney RD, Blake S, Bremer PT, Zhou B, Hwang CS, Poklis JL, Janda KD, Banks ML.

Neuropharmacology. 2019 Nov 1;158:107730. doi: 10.1016/j.neuropharm.2019.107730. Epub 2019 Jul 29.

PMID:
31369740
4.

Experimental design and analysis for consideration of sex as a biological variable.

Diester CM, Banks ML, Neigh GN, Negus SS.

Neuropsychopharmacology. 2019 Dec;44(13):2159-2162. doi: 10.1038/s41386-019-0458-9. Epub 2019 Jul 5. No abstract available.

PMID:
31277076
5.

Pharmacological validation of a translational model of cocaine use disorder: Effects of d-amphetamine maintenance on choice between intravenous cocaine and a nondrug alternative in humans and rhesus monkeys.

Lile JA, Johnson AR, Banks ML, Hatton KW, Hays LR, Nicholson KL, Poklis JL, Rayapati AO, Rush CR, Stoops WW, Negus SS.

Exp Clin Psychopharmacol. 2019 Jul 1. doi: 10.1037/pha0000302. [Epub ahead of print]

PMID:
31259593
6.

Conjugate vaccine produces long-lasting attenuation of fentanyl vs. food choice and blocks expression of opioid withdrawal-induced increases in fentanyl choice in rats.

Townsend EA, Blake S, Faunce KE, Hwang CS, Natori Y, Zhou B, Bremer PT, Janda KD, Banks ML.

Neuropsychopharmacology. 2019 Sep;44(10):1681-1689. doi: 10.1038/s41386-019-0385-9. Epub 2019 May 2.

PMID:
31043682
7.

Effects of repeated kappa-opioid receptor agonist U-50488 treatment and subsequent termination on intracranial self-stimulation in male and female rats.

Faunce KE, Banks ML.

Exp Clin Psychopharmacol. 2019 Apr 22. doi: 10.1037/pha0000287. [Epub ahead of print]

PMID:
31008640
8.

Sex differences in opioid reinforcement under a fentanyl vs. food choice procedure in rats.

Townsend EA, Negus SS, Caine SB, Thomsen M, Banks ML.

Neuropsychopharmacology. 2019 Nov;44(12):2022-2029. doi: 10.1038/s41386-019-0356-1. Epub 2019 Feb 28.

PMID:
30818323
9.

Characterization of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(indole-7-carboxamido)morphinan (NAN) as a Novel Opioid Receptor Modulator for Opioid Use Disorder Treatment.

Obeng S, Jali A, Zheng Y, Wang H, Schwienteck KL, Chen C, Stevens DL, Akbarali HI, Dewey WL, Banks ML, Liu-Chen LY, Selley DE, Zhang Y.

ACS Chem Neurosci. 2019 May 15;10(5):2518-2532. doi: 10.1021/acschemneuro.9b00038. Epub 2019 Feb 21.

10.

Testing the 10 most wanted: a preclinical algorithm to screen candidate opioid use disorder medications.

Banks ML, Townsend EA, Negus SS.

Neuropsychopharmacology. 2019 May;44(6):1011-1012. doi: 10.1038/s41386-019-0336-5. Epub 2019 Feb 9. Review. No abstract available.

PMID:
30739125
11.

Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats.

Schwienteck KL, Faunce KE, Rice KC, Obeng S, Zhang Y, Blough BE, Grim TW, Negus SS, Banks ML.

Neuropharmacology. 2019 May 15;150:200-209. doi: 10.1016/j.neuropharm.2019.01.020. Epub 2019 Jan 18.

PMID:
30660628
12.

Impaired cognitive behavioral flexibility following methamphetamine or high caloric diet consumption: a common 5-HT2C mechanism?

Banks ML.

Neuropsychopharmacology. 2019 Feb;44(3):461-462. doi: 10.1038/s41386-018-0243-1. Epub 2018 Oct 24. No abstract available.

PMID:
30644441
13.

Effects of acute and repeated treatment with serotonin 5-HT2A receptor agonist hallucinogens on intracranial self-stimulation in rats.

Sakloth F, Leggett E, Moerke MJ, Townsend EA, Banks ML, Negus SS.

Exp Clin Psychopharmacol. 2019 Jun;27(3):215-226. doi: 10.1037/pha0000253. Epub 2019 Jan 10.

PMID:
30628811
14.

Stress as a Risk Factor for Substance Use Disorders: A Mini-Review of Molecular Mediators.

Mukhara D, Banks ML, Neigh GN.

Front Behav Neurosci. 2018 Dec 21;12:309. doi: 10.3389/fnbeh.2018.00309. eCollection 2018. Review.

15.

Role of mu-opioid agonist efficacy on antinociceptive interactions between mu agonists and the nociceptin opioid peptide agonist Ro 64-6198 in rhesus monkeys.

Cornelissen JC, Steele FF, Tenney RD, Obeng S, Rice KC, Zhang Y, Banks ML.

Eur J Pharmacol. 2019 Feb 5;844:175-182. doi: 10.1016/j.ejphar.2018.12.021. Epub 2018 Dec 12.

PMID:
30552903
16.

Immunopharmacotherapies for Treating Opioid Use Disorder.

Banks ML, Olson ME, Janda KD.

Trends Pharmacol Sci. 2018 Nov;39(11):908-911. doi: 10.1016/j.tips.2018.08.001. Review.

17.

Effects of repeated treatment with methcathinone, mephedrone, and fenfluramine on intracranial self-stimulation in rats.

Suyama JA, Banks ML, Negus SS.

Psychopharmacology (Berl). 2019 Mar;236(3):1057-1066. doi: 10.1007/s00213-018-5029-y. Epub 2018 Sep 19.

PMID:
30232529
18.

Sex differences in the effectiveness of buprenorphine to decrease rates of responding in rhesus monkeys.

Schwienteck KL, Negus SS, Banks ML.

Behav Pharmacol. 2019 Jun;30(4):358-362. doi: 10.1097/FBP.0000000000000437.

PMID:
30212383
19.

Interactions between Cocaine and the Putative Allosteric Dopamine Transporter Ligand SRI-31142.

Moerke MJ, Ananthan S, Banks ML, Eltit JM, Freitas KC, Johnson AR, Saini SK, Steele TWE, Negus SS.

J Pharmacol Exp Ther. 2018 Nov;367(2):222-233. doi: 10.1124/jpet.118.250902. Epub 2018 Aug 27.

20.

Amphetamine maintenance differentially modulates effects of cocaine, methylenedioxypyrovalerone (MDPV), and methamphetamine on intracranial self-stimulation and nucleus accumbens dopamine in rats.

Johnson AR, Banks ML, Selley DE, Negus SS.

Neuropsychopharmacology. 2018 Jul;43(8):1753-1762. doi: 10.1038/s41386-018-0071-3. Epub 2018 Apr 19.

21.

Application of Receptor Theory to the Design and Use of Fixed-Proportion Mu-Opioid Agonist and Antagonist Mixtures in Rhesus Monkeys.

Cornelissen JC, Obeng S, Rice KC, Zhang Y, Negus SS, Banks ML.

J Pharmacol Exp Ther. 2018 Apr;365(1):37-47. doi: 10.1124/jpet.117.246439. Epub 2018 Jan 12.

22.

Remifentanil maintains lower initial delayed nonmatching-to-sample accuracy compared to food pellets in male rhesus monkeys.

Hutsell BA, Banks ML.

Exp Clin Psychopharmacol. 2017 Dec;25(6):441-447. doi: 10.1037/pha0000154.

23.

Additive and subadditive antiallodynic interactions between μ-opioid agonists and N-methyl D-aspartate antagonists in male rhesus monkeys.

Cornelissen JC, Steele FF, Rice KC, Nicholson KL, Banks ML.

Behav Pharmacol. 2018 Feb;29(1):41-52. doi: 10.1097/FBP.0000000000000336.

24.

Maintenance on naltrexone+amphetamine decreases cocaine-vs.-food choice in male rhesus monkeys.

Moerke MJ, Banks ML, Cheng K, Rice KC, Negus SS.

Drug Alcohol Depend. 2017 Dec 1;181:85-93. doi: 10.1016/j.drugalcdep.2017.09.020. Epub 2017 Oct 13.

25.

The monoacylglycerol lipase inhibitor KML29 with gabapentin synergistically produces analgesia in mice.

Crowe MS, Wilson CD, Leishman E, Prather PL, Bradshaw HB, Banks ML, Kinsey SG.

Br J Pharmacol. 2017 Dec;174(23):4523-4539. doi: 10.1111/bph.14055. Epub 2017 Nov 20.

26.

Development of a Clinically Viable Heroin Vaccine.

Bremer PT, Schlosburg JE, Banks ML, Steele FF, Zhou B, Poklis JL, Janda KD.

J Am Chem Soc. 2017 Jun 28;139(25):8601-8611. doi: 10.1021/jacs.7b03334. Epub 2017 Jun 20.

27.

Utility of Nonhuman Primates in Substance Use Disorders Research.

Banks ML, Czoty PW, Negus SS.

ILAR J. 2017 Dec 1;58(2):202-215. doi: 10.1093/ilar/ilx014. Review.

28.
29.

Role of d-amphetamine and d-methamphetamine as active metabolites of benzphetamine: Evidence from drug discrimination and pharmacokinetic studies in male rhesus monkeys.

Banks ML, Snyder RW, Fennell TR, Negus SS.

Pharmacol Biochem Behav. 2017 May;156:30-38. doi: 10.1016/j.pbb.2017.03.008. Epub 2017 Mar 31.

30.

Abuse-related effects of subtype-selective GABAA receptor positive allosteric modulators in an assay of intracranial self-stimulation in rats.

Schwienteck KL, Li G, Poe MM, Cook JM, Banks ML, Stevens Negus S.

Psychopharmacology (Berl). 2017 Jul;234(14):2091-2101. doi: 10.1007/s00213-017-4615-8. Epub 2017 Apr 1.

31.

Utility of preclinical drug versus food choice procedures to evaluate candidate medications for methamphetamine use disorder.

Banks ML.

Ann N Y Acad Sci. 2017 Apr;1394(1):92-105. doi: 10.1111/nyas.13276. Epub 2016 Dec 9. Review.

32.

Insights from Preclinical Choice Models on Treating Drug Addiction.

Banks ML, Negus SS.

Trends Pharmacol Sci. 2017 Feb;38(2):181-194. doi: 10.1016/j.tips.2016.11.002. Epub 2016 Dec 2. Review.

33.
34.

Effects of 21-day d-amphetamine and risperidone treatment on cocaine vs food choice and extended-access cocaine intake in male rhesus monkeys.

Hutsell BA, Negus SS, Banks ML.

Drug Alcohol Depend. 2016 Nov 1;168:36-44. doi: 10.1016/j.drugalcdep.2016.08.637. Epub 2016 Sep 5.

35.

Cocaine-like discriminative stimulus effects of amphetamine, cathinone, methamphetamine, and their 3,4-methylenedioxy analogs in male rhesus monkeys.

Smith DA, Blough BE, Banks ML.

Psychopharmacology (Berl). 2017 Jan;234(1):117-127. doi: 10.1007/s00213-016-4444-1. Epub 2016 Oct 5.

37.

Pharmacokinetic-Pharmacodynamic (PKPD) Analysis with Drug Discrimination.

Negus SS, Banks ML.

Curr Top Behav Neurosci. 2018;39:245-259. doi: 10.1007/7854_2016_36. Review.

38.

Sex differences in abuse-related neurochemical and behavioral effects of 3,4-methylenedioxymethamphetamine (MDMA) in rats.

Lazenka MF, Suyama JA, Bauer CT, Banks ML, Negus SS.

Pharmacol Biochem Behav. 2017 Jan;152:52-60. doi: 10.1016/j.pbb.2016.08.004. Epub 2016 Aug 24.

39.

Dissociable effects of the prodrug phendimetrazine and its metabolite phenmetrazine at dopamine transporters.

Solis E Jr, Suyama JA, Lazenka MF, DeFelice LJ, Negus SS, Blough BE, Banks ML.

Sci Rep. 2016 Aug 12;6:31385. doi: 10.1038/srep31385.

40.

Development of a translational model to screen medications for cocaine use disorder I: Choice between cocaine and food in rhesus monkeys.

Johnson AR, Banks ML, Blough BE, Lile JA, Nicholson KL, Negus SS.

Drug Alcohol Depend. 2016 Aug 1;165:103-10. doi: 10.1016/j.drugalcdep.2016.05.021. Epub 2016 May 28.

41.

Effects of 7-day repeated treatment with the 5-HT2A inverse agonist/antagonist pimavanserin on methamphetamine vs. food choice in male rhesus monkeys.

Banks ML.

Drug Alcohol Depend. 2016 Aug 1;165:260-4. doi: 10.1016/j.drugalcdep.2016.05.014. Epub 2016 May 27.

42.

Cocaine-like discriminative stimulus effects of alpha-pyrrolidinovalerophenone, methcathinone and their 3,4-methylenedioxy or 4-methyl analogs in rhesus monkeys.

Smith DA, Negus SS, Poklis JL, Blough BE, Banks ML.

Addict Biol. 2017 Sep;22(5):1169-1178. doi: 10.1111/adb.12399. Epub 2016 Apr 6.

43.

Methamphetamine-like discriminative stimulus effects of bupropion and its two hydroxy metabolites in male rhesus monkeys.

Banks ML, Smith DA, Blough BE.

Behav Pharmacol. 2016 Apr;27(2-3 Spec Issue):196-203. doi: 10.1097/FBP.0000000000000224.

44.

Cocaine-like discriminative stimulus effects of phendimetrazine and phenmetrazine in rats.

Bauer CT, Negus SS, Blough BE, Banks ML.

Behav Pharmacol. 2016 Apr;27(2-3 Spec Issue):192-5. doi: 10.1097/FBP.0000000000000225.

45.

The Selective Monoacylglycerol Lipase Inhibitor MJN110 Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model.

Wilkerson JL, Niphakis MJ, Grim TW, Mustafa MA, Abdullah RA, Poklis JL, Dewey WL, Akbarali H, Banks ML, Wise LE, Cravatt BF, Lichtman AH.

J Pharmacol Exp Ther. 2016 Apr;357(1):145-56. doi: 10.1124/jpet.115.229971. Epub 2016 Jan 20.

46.

Abuse-related neurochemical and behavioral effects of cathinone and 4-methylcathinone stereoisomers in rats.

Hutsell BA, Baumann MH, Partilla JS, Banks ML, Vekariya R, Glennon RA, Negus SS.

Eur Neuropsychopharmacol. 2016 Feb;26(2):288-297. doi: 10.1016/j.euroneuro.2015.12.010. Epub 2015 Dec 11.

47.

Nicotine Enhances the Hypnotic and Hypothermic Effects of Alcohol in the Mouse.

Slater CA, Jackson A, Muldoon PP, Dawson A, O'Brien M, Soll LG, Abdullah R, Carroll FI, Tapper AR, Miles MF, Banks ML, Bettinger JC, Damaj IM.

Alcohol Clin Exp Res. 2016 Jan;40(1):62-72. doi: 10.1111/acer.12918.

48.

Relationship between discriminative stimulus effects and plasma methamphetamine and amphetamine levels of intramuscular methamphetamine in male rhesus monkeys.

Banks ML, Smith DA, Kisor DF, Poklis JL.

Pharmacol Biochem Behav. 2016 Feb;141:58-65. doi: 10.1016/j.pbb.2015.12.001. Epub 2015 Dec 3.

49.

Abuse-Related Neurochemical Effects of Para-Substituted Methcathinone Analogs in Rats: Microdialysis Studies of Nucleus Accumbens Dopamine and Serotonin.

Suyama JA, Sakloth F, Kolanos R, Glennon RA, Lazenka MF, Negus SS, Banks ML.

J Pharmacol Exp Ther. 2016 Jan;356(1):182-90. doi: 10.1124/jpet.115.229559. Epub 2015 Oct 15.

50.

Negative allosteric modulation of GABAA receptors inhibits facilitation of brain stimulation reward by drugs of abuse in C57BL6/J mice.

Tracy ME, Banks ML, Shelton KL.

Psychopharmacology (Berl). 2016 Feb;233(4):715-25. doi: 10.1007/s00213-015-4155-z. Epub 2015 Nov 27.

Supplemental Content

Loading ...
Support Center